Corteva Q3 Results: Sales Fall 9% as Brazil Weakness Hits Outlook

Corteva Q3 results showed net sales falling 9 per cent to $1.59 billion as the crop protection company swung to a loss, it said on Wednesday, November 11. The company also updated its full-year 2026 outlook to reflect weaker-than-expected market conditions in Brazil, and its shares fell sharply the next day.

The results are Corteva’s first since it completed the separation of its Seed business, now Vylor, on October 1, and are presented on a pro forma basis for the stand-alone crop protection company. Corteva reported a pro forma GAAP loss from continuing operations of $54 million, compared with income of $60 million a year earlier.

Corteva Q3 results: the numbers

Organic sales also fell 9 per cent in the quarter ended September 30, the company said in a statement. Volume declined 2 per cent and price fell 7 per cent, with competitive pressure on older crop protection molecules in Brazil and on acetochlor in the US.

Adjusted pro forma operating Ebitda dropped 17 per cent to $222 million, from $268 million a year earlier, which translated into 140 basis points of margin erosion. Adjusted pro forma operating earnings per share came in at $0.06, down 57 per cent, while the pro forma GAAP loss per share was $0.08.

The weakness was concentrated in Latin America, where net sales fell 28 per cent to $570 million and organic sales dropped 31 per cent. Corteva said volumes in the region declined 24 per cent because of elevated channel inventory and delayed purchasing, as farmers faced tight liquidity and high interest rates.

Other regions held up. North America posted 7 per cent organic growth, with volume up 19 per cent, and EMEA grew organic sales by 14 per cent. Asia Pacific recorded 5 per cent organic growth on the back of demand for new products.

Chief executive officer Luke Kissam said new products performed strongly and productivity delivered. He added that acetochlor pricing in the US was in line with expectations, “but Brazil was materially weaker than anticipated.”

Revised 2026 guidance and market reaction

Under the revised Corteva guidance, the company now expects adjusted pro forma operating Ebitda of $1.1 billion to $1.125 billion for 2026. It expects adjusted pro forma operating earnings per share of $0.76 to $0.80.

The company said crop protection conditions have become tougher, particularly in Brazil, where financing costs are elevated and buyers are purchasing just in time. It added that demand for its differentiated new products remains strong and that performance outside Latin America has been resilient.

The quarter fell short of Wall Street forecasts. Analysts had expected adjusted earnings of about $0.10 per share on sales of around $1.77 billion, according to Investing.com. Corteva shares fell more than 20 per cent in trading on Thursday, November 12, according to several market reports, and hit a new 52-week low.

For the first nine months of 2026, pro forma net sales fell 1 per cent to $5.36 billion. Adjusted pro forma operating Ebitda was $943 million, broadly flat, and the margin widened by 30 basis points to 17.6 per cent.

The board has also authorised Corteva’s first common dividend since the spin-off, the company said.

Why it matters for investors and what comes next

The Corteva Q3 results give investors their first look at Corteva as a pure-play crop protection business, and they highlight how exposed that business is to Brazil. Latin America accounted for more than a third of third-quarter sales, so swings in Brazilian farm credit and channel stock can move group earnings sharply.

The results also show competitive pricing pressure on mature chemistries late in their lifecycle. Corteva is leaning on newer products and cost savings to offset that pressure, and said it expects net pre-tax restructuring charges of about $130 million to $140 million in 2026 as it reshapes its manufacturing network.

Management discussed the results with analysts on a webcast on November 12. Investors will look for further detail on Brazilian inventory levels, the pace of new product launches and any early view on 2027. Corteva is not the only large US group reshaping itself through a break-up; CVS Health plans to separate its pharmacy business from Aetna.

Also Read: October CPI report: hot inflation lifts odds of a December Fed hike

The full figures are in Corteva’s third-quarter earnings release. For more company earnings coverage, read our report on Berkshire Hathaway’s Q3 results or browse the latest business news on Business ERA.